Santhera Pharmaceuticals Holding AG Sustainability Reports
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases. Its lead product is AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy.
Sector: Manufacturing
Country: Switzerland
Exchange: SIX Swiss Exchange
LEI: 54930035HAOFTTQH0U85
FIGI: BBG001SNBR77
10 reports from 2011 to 2025